Asset profile
Pirenzepine (topical)
Small molecule
Evidence outlook · registrational
HIV: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT05005078: The study randomly assigned 16 participants to topical WST-057 or placebo, with Part A open-label and Part B double-blinded. Its primary endpoints were laboratory, vital-sign, ECG, and skin-safety measures rather than a hard clinical outcome, and no primary-endpoint results were posted; the small sample also limits the strength of the evidence.
Also in development:Diabetic Peripheral Neuropathic Pain · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.